ClinicalTrials.gg
Not yet recruitingNCT06059287Updated Sep 28, 2023

The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

An interventional study of Henagliflozin and Metformin in Obesity, Type 2 Diabetes and Sodium-glucose Co-transporter-2 Inhibitor, sponsored by RenJi Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity by RenJi Hospital — 6 open to participants now, 6 under way, none of them phase 3. Obesity · RenJi Hospital.

Started
2023
with 3 others
No phase
5 of 10
4 open now
Registered
6th of 10
by date

Among the 10 studies in Obesity by RenJi Hospital, this one is one of 4 that started in 2023, is one of 5 with no phase, and was the 6th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 10 studies in Obesity by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by RenJi Hospital, or all of them as a file.
02

Study summary

This is a prospective, randomized, open-label, active drug controlled clinical trial that aims to compare the effects of henagliflozin or metformin on myocardial tissue level characteristics in type 2 diabetes patients with obesity. Eligible subjects with type 2 diabetes before randomisation and fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1 ratio to henagliflozin 10 mg once a day or metformin 1000 mg twice a day and treated for 24 weeks. The study includes five visits.

Read the detailed description

MRI scanning will be assessed at baseline and at the end of the treatment period in order to to assess the cardiac morphology, cardiac function, and myocardial tissue characteristics. The cardiac MRI examination will be performed in accordance with a pre-defined MRI protocol. Images from all sites will be analyzed centrally at the core-lab using a dedicated software package and certified analysts.

03

Conditions studied

  • Obesity
  • Type 2 Diabetes
  • Sodium-glucose Co-transporter-2 Inhibitor
  • Myocardial Fibrosis
  • Magnetic Resonance Imaging

Keywords

  • Metformin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with type 2 diabetes newly diagnosed based on the WHO (1999) criteria;
  • levels >=7.0% and \<=8.0%;
  • Females or males ≥18 years up to 75 years of age.

Exclusion criteria

Exclusion Criteria:

  • Females or males \<18 years.
  • Clinical diagnosis of type 1 diabetes and other types of diabetes.
  • Blood pressure at screening that would require a change in blood pressure treatment over the study period.
  • History of stroke or other cerebrovascular disease.
  • Any of the following cardiovascular diseases:

    1. Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function
    2. Unstable heart failure or any heart failure with class III and IV
    3. Significant valvular disease
    4. Significant peripheral artery disease
  • Active requiring treatment at the time of visit 0.
  • Patients with severe hepatic impairment.
  • Unstable or rapidly progressing renal disease.
  • Ongoing treatment with loop diuretics.
  • Estimated (eGFR) \<45 mL/min/1.73 m2.
  • Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Henagliflozin

    Henagliflozin 10mg qd po

    Drug: Henagliflozin

  • Active comparator
    Metformin

    Metformin 1000mg bid po

    Drug: Metformin

Interventions

  • Henagliflozin 10mg qd po

    Also known as: SHR3824

  • Metformin 1000mg bid po

    Also known as: Metformin Hydrochloride

06

What researchers measure

Primary outcomes

  1. Extra-cellular volume fraction

    To compare the effects of henagliflozin and metformin on extra-cellular volume fraction

    Time frame: baseline and week 24

Secondary outcomes

  1. Mean Change in HbA1c Levels

    To compare the effects of henagliflozin and metformin on HbA1c Levels

    Time frame: baseline and week 24

  2. Mean change in body mass index

    To compare the effects of henagliflozin and metformin on body mass index

    Time frame: baseline and week 24

  3. Mean change in blood pressure

    To compare the effects of henagliflozin and metformin on blood pressure

    Time frame: baseline and week 24

  4. Mean change in level of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    To compare the effects of henagliflozin and metformin on level of Homeostatic Model Assessment of Insulin Resistance

    Time frame: baseline and week 24

  5. Native T2 mapping

    To compare the effects of henagliflozin and metformin on native T2 mapping

    Time frame: baseline and week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Dec 2025, 26 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 26 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartEst.
Oct 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059287
Lead sponsor
RenJi Hospital
Responsible party
Jing Ma (Executive Officer of Endocrinology Department, RenJi Hospital) — Principal investigator
First posted
Sep 28, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 28, 2023

Study contacts

Rong Huang
Contact
renjihuangrong@163.com
68-021-68383424
YiCheng Qi
Contact
qiyicheng@renji.com
68-021-68383420
Jing Ma
principal investigator · RenJi Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Henagliflozin

Start the discussion